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Background: In vivo tissue regeneration depends on migration of stem cells into injured areas, their differentiation
into specific cell types, and their interaction with other cells that are necessary to generate new tissue. Human
mesenchymal stem cells, a subset of bone marrow stromal cells (BMSCs), can migrate and differentiate into
osteoblasts in bone tissue. This can be facilitated by recombinant growth factors and cytokines. In many animal
species, the availability of genomic sequences, recombinant proteins, and/or antibodies is limited so that new
approaches are needed to generate resources that facilitate migration of stem cells into tissue defect areas. Here
we used bone marrow stromal cells of human, ovine, equine, and canine origin to generate hypoxia-conditioned
media (HCM) in order to attract BMSCs of the respective species in migration assays.
Results: We show that HCM contain attractors even more potent than vascular endothelial growth factor and can
therefore be used in many animal species without the need for purified proteins.
Conclusion: Generation of HCM is easy and cheap compared to preparation and purification of protein fractions
and/or recombinant proteins. Hence, HCM could be applied in large animals (e.g. sheep, horse, dogs) for attraction
of BMSCs into tissue defects caused by tumor resection or trauma.
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In vivo tissue regeneration depends on migration of stem
cells into injured areas, their differentiation into specific cell
types, and their interaction with other cells that are ne-
cessary to generate new tissue. Mesenchymal stem cells,
a subset of BMSCs, can migrate and differentiate into
osteoblasts in bone tissue [1,2]. Human BMSCs show sig-
nificant chemotactic responses to several factors, including
platelet-derived growth factor (PDGF), vascular endothelial
growth factor (VEGF), insulin-like growth factor (IGF-1),
interleukin-8 (IL-8), bone-morphogenetic protein (BMP)-4,
and BMP-7 [1]. We have previously shown that human
BMSCs can be attracted into three-dimensional scaffolds
following a gradient of recombinant human stromal cell-
derived factor 1α (SDF-1α) [3]. BMSCs themselves secrete
significant levels of chemoattractive agents like VEGF,* Correspondence: Angela.Roesen-Wolff@uniklinikum-dresden.de
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distribution, and reproduction in any mediummonocyte chemoattractant protein-1 (MCP-1), macrophage
inflammatory protein-1α (MIP-1α), MIP-1β, and monokine
induced by IFN-γ (MIG) [4]. Secretion of VEGF from
these cells can be upregulated by hypoxic conditions in a
hypoxia-inducible factor-1 (HIF-1)-dependent way [5].
Many chemoattractive agents of human origin are avail-
able as recombinant proteins that facilitate the study of
migration processes in human cells. However, molecular
biological characterization of BMSC migration in large
animal species is difficult because of the limited availability
of genomic sequences, recombinant proteins, and/or anti-
bodies so that new experimental approaches are required.
Here we used BMSCs of human, ovine, equine, and canine
origin to generate hypoxia-conditioned media (HCM) in
order to attract BMSCs of the respective species in migra-
tion assays. We show that HCM is an even more potent
attractor than purified VEGF and can therefore be used in
many animal species without the need for recombinant
or otherwise purified proteins. We were able to show
the presence of VEGF and high-mobility group proteintral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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associated protein that binds to DNA and alters its
conformation [6]. Released by hypoxic cells, it binds to the
receptor for advanced glycation end-products (RAGE) and
activates MAP kinase cascades [6]. It plays an important
role in the process of BMSC migration [7].
Methods
Isolation and cultivation of human, ovine, equine, and
canine BMSCs
Human BMSCs were obtained from the Translational
Biomedical Research Group, Center for Regenerative
Therapies, Dresden. Ovine bone marrow aspirates obtained
from the chest of a merino sheep were provided by
the Department of Orthopaedics, University Clinic Carl
Gustav Carus, Dresden. Equine and canine BMSCs were
isolated by the Department of Veterinary Anatomy,
University of Giessen. Density gradient centrifugation
by Ficoll (Biochrom, Berlin, Germany) was performed
to enrich human, ovine, equine, and canine bone marrow
stromal cells (BMSCs). Thereafter, they were cultured in
T-175 flasks (Greiner Bio-One, Frickenhausen, Germany)
in alpha medium (Biochrom) containing 10% fetal calf serum
(FCS) (Sigma), 1% L-glutamine (PAA, Pasching, Austria)
and 1% penicillin/streptomycin (PAA) in a humidified
atmosphere with 20% O2, 5% CO2 at 37°C (Thermo
Scientific BBD 6220 CO2 Incubator, Omnilab, Bremen,
Germany). After 5 days the culture medium was ex-
changed and thereafter every 3-4 days until the culture
reached 80-90% confluence.
Cultivation of HUVECs
Human umbilical vein endothelial cells (HUVECs) were
purchased from Promocell, Heidelberg, Germany and cul-
tured in Endothelial Cell Growth Medium (ready-to-use,
Promocell) without further supplements.
Characterization of human, ovine, equine, and canine BMSCs
CD105 and CD271 MicroBead kits (Miltenyi Biotec) were
used for magnetic labelling and positive selection of the
BMSCs according to the manufacturer’s instructions.
Generation of HCM
Human, ovine, equine, and canine BMSCs were cultured
in T-175 flasks in alpha medium containing 10% fetal
calf serum,1% L-glutamine and 1% penicillin/streptomycin
(PAA) in a normoxic chamber until the cultures reached
80-90% confluence. After the passage, cells were cultured
overnight in alpha medium containing 5% fetal calf
serum,1% L-glutamine and 1% penicillin/streptomycin
(PAA). On the next day, cultures were transferred into an-
other incubator and cultured in a humidified atmosphere
with 1% O2, 5% CO2 at 37°C for 48 h (Thermo Scientific
HERAcell 150i, Waltham, MA, USA). Thereafter, thesupernatants (HCM) were aliquoted into 2 ml tubes
(Eppendorf) and stored at -80°C to be used in migration
assays. Control media were generated in the same way but
at normoxic conditions.
Human, ovine, equine and canine VEGF and HMGB1 ELISA
of HCM
In order to quantify the content of VEGF and HMGB1 in
human, ovine, equine and canine HCM, an enzyme-linked
immunosorbent assay (ELISA) was performed according to
the manufacturer’s instruction. VEGF kits for human and
canine ELISA were from R&D (Abingdon, England), for
ovine from TSZ Biotang (Waltham, USA) and for equine
from Genorise (Philadelphia, USA). HMGB1 kit was from
IBL (Hamburg, Germany).
Migration assay
Cell migration assays were performed in Corning
Transwell®-96 permeable support chambers with porous
polyester membranes with a pore size of 8.0 μm (Corning
Incorporated Life Sciences, Munich, Germany). Human
BMSCs (P2-11), ovine BMSCs (P5-P12), equine BMSCs
(P4-7), and canine BMSCs (P5-8) were resuspended at
5 × 104 cells/ml in Alpha Medium supplemented with
1% L-glutamine, 1% penicillin/streptomycin, without BSA
and seeded into the upper chamber. HUVECs (P6) were
resuspended in endothelial cell growth medium without
supplements. 200 ng/ml human, ovine, equine and canine
VEGF-A (all from Biomol, Hamburg, Germany) or HCM
from corresponding MSCs were used as chemoattractive
agents in the lower compartment. The 96-well plate
was incubated overnight-night at 37°C in a normoxic
incubator. The cells on the upper membrane compart-
ment were removed manually. Then the migrated cells
adhering to the underside of the membrane and from the
lower chamber were dislodged by incubating the in-
serts in 0.25% trypsin for 4 min followed by treatment with
trypsin neutralisation solution (Promocell). AlamarBlue®
(Invitrogen, Darmstadt, Germany) was used to stain the
cells overnight. Cell number was calculated at excitation
560 nm/emission 590 nm using Tecan microplate reader
(Männedorf, Switzerland).
Results are described as the mean percentage of mi-
grated cells over control cells, the latter show basal
migration without chemotactic signal. Each condition
was tested in four wells, experiments for human BMSCs
and ovine BMSCs were repeated six times, for HUVEC,
equine BMSCs and canine BMSCs three experiments
were performed.
Statistical analysis
T test was performed using the program available at http://
www.daten-consult.de/forms/ttestunabh.html website.
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VEGF and HMGB1 ELISAs of human, ovine, equine, and
canine HCM
We performed ELISAs in order to determine the amount
of VEGF and HMGB1 released from BMSCs under hypoxic
conditions. When we started our experiments, only human
VEGF kit was available; therefore, we tested if ovine, equine,
or canine VEGF could be detected by antibodies directed
against human VEGF by using human, ovine, equine,
and canine HCM. As expected, human VEGF could be
detected at a concentration of 1.99 ng/ml in human HCM.
In canine HCM, we determined a concentration of
1.96 ng/ml VEGF. Human VEGF ELISA antibody did
not interact with ovine and equine HCM, indicating that
ovine and equine VEGF differ in their amino acid compos-
ition from human VEGF. Alignment of human, ovine,
equine, and canine VEGF amino acid sequences revealed a
high degree of sequence homology (Figure 1).
Although canine VEGF sequences harbour an insertion
of 24 amino acids, only two other amino acids (indicated
in light blue) differ from the human VEGF sequence.
These differences did not interfere with interaction of
the human VEGF antibody. However, ovine and equine
VEGF differ from human VEGF in four amino acid posi-
tions (indicated in yellow or green, respectively). Sequence
alteration caused by amino acid exchanges might explain
why VEGF of these species cannot be recognized by the
human ELISA antibody. Using ovine, equine, and canine
VEGF ELISA, we were able to demonstrate the presence
and determine the concentrations of VEGF in all HCMs
used in this study (Table 1). Since HMGB1 is an important
alarmin cytokine produced by cells under hypoxic con-
ditions, we wanted to determine if it is present in HCM
and is one of the factors that make HCM such a potent
chemoattractive substance for BMSCs. Indeed, highFigure 1 Alignment of human [GenBank: AY047581.1], ovine [GenBank
and canine [NCBI Reference Sequence: NM_001003175.2] VEGF amino a
yellow (ovine), green (equine), or blue (canine).concentrations of HMGB1 (between 8 and 25 ng/ml)
were detected in all HCMs (Table 1).
Control media contained less than 9 pg/ml (human and
canine), 30 pg/ml (ovine) or 1 pg/ml (equine) VEGF-A and
2.5 ng/ml (all species) HMBG1.
Chemoattraction of human, ovine, equine, and canine
BMSCs by HCM
In order to determine the capacity of HCM to attract
BMSCs of human, ovine, equine, and canine origin, we
performed migration assays. Human umbilical vein endo-
thelial cells (HUVECs) attracted by recombinant human
VEGF (200 ng/ml) served as positive control. As shown in
Figure 2, migration of HUVECs increased seven-fold under
these conditions. Migration of human BMSCs could be in-
creased 2.36-fold by exposure to 200 ng/ml VEGF. In com-
parison to control media, human HCM was significantly
more potent (p = 0.029). Although human HCM contained
only 1.99 ng/ml VEGF (as determined by ELISA), migration
of human BMSCs could be enhanced 5.33-fold indicating
that HCM contains an additional chemoattractive agent,
namely HMGB1. Ovine BMSCs did not respond to human
recombinant VEGF (data not shown) indicating that the
minor differences detected between human and ovine
VEGF (only four amino acids exchanged) were sufficient
to result in species specificity. This explains why ovine
VEGF in ovine HCM could only be detected by the
species-specific ovine VEGF-A ELISA kit. Migration of
ovine BMSCs could be increased 5.54-fold by ovine HCM
and only 4.3-fold by ovine VEGF (200 ng/ml) (Figure 2).
Thus, ovine HCM was significantly more potent than
control media (p = 0.016). The same was true of equine
BMSCs. Migration could be boosted 3.6-fold when equine
HCM was used (p < 0.001). Canine BMSCs migrated less
efficiently compared to the other species. However, canine: AF071015.1], equine [NCBI Reference Sequence: NM_001081821.1]
cid sequences. Differences to the human VEGF sequence are marked in
Table 1 Concentrations of VEGF-A in human, ovine,









VEGF-A 1990 1428 40 1960
HMGB1 8077 12747 13676 25151
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canine VEGF was not a potent inducer of migration.
Discussion
The use of BMSCs in orthopaedic surgery has gained
importance over the last years and is rapidly becoming
clinical routine. BMSCs are also interesting tools in human
and veterinary medicine in general because they are able to
migrate and differentiate into osteoblasts in bone tissue [1],
they have been proven to regenerate bone combined with
carriers [8], and they sustain skin repair in canine animal
models by influencing cellular proliferation and angio-
genesis, and via modulation of mRNA expression of
wound-healing factors [9]. Recently, BMSCs were used
successfully in the treatment of horses affected by ten-
donitis and desmitis [10]. Usually these high perform-
ance horses develop skeletal or muscular injuries that
are difficult to treat, and after many surgeries they are
not able to resume sports activity. Clinical studies have
demonstrated that horses treated with equine BMSCs
were able to resume previous levels of sport activity
[9]. Furthermore, equine autologous cell products are
able to stimulate and activate BMSCs facilitating treat-
ment and healing of chronic lesions in these animals
[11]. Human BMSCs have been demonstrated to migrate
towards chemoattractive agents such as platelet-derivedFigure 2 Migration (in%) of human, ovine, equine, and canine BMSCs
control. Differences between migration of BMSCs attracted by control med
statistically significant.growth factor (PDGF), epidermal growth factor (EGF),
and vascular epidermal growth factor (VEGF) [10] as
well as towards insulin-like growth factor (IGF-1),
interleukin-8 (IL-8), bone-morphogenetic protein (BMP)-4,
and BMP-7 [1]. BMSCs are also able to influence re-
pair by secreting growth factors, anti-apoptotic factors,
and anti-inflammatory factors [1]. Here, we investigated
the directional migration of human, ovine, equine and ca-
nine BMSCs towards hypoxia conditioned media (HCM),
and found that they contain high concentrations of the
potent chemoattractive agent HMGB1, an important
alarmin cytokine.
HMGB1 is a non-histone nucleosomal protein which
is expressed in all mammal cells, a critical mediator of sys-
temic and local inflammation [7]. It is a chemoattractant,
which is directing migration of smooth muscle cells, myo-
blasts, mesoangioblasts, hematopoietic stem cells, dendritic
cells, and human MSCs. Moreover, HMGB1 causes the
differentiation of MSCs into osteoblasts [7]. The presence
of HMGB1 in HCM explains why they are significantly
stronger chemoattractants than pure VEGF.
Our data suggest that HCM have a potent species-
specific chemoattractive capacity. Cell migration could
be enhanced from 1.4 to 5.54 times depending on the
species tested. In comparison to that, pure recombinant
VEGF (200 ng/ml) increased migration only from 0 to
4.3-fold. Canine VEGF did not enhance migration of
canine BMSCs when compared to control media. However,
8.1% of the canine BMSCs already migrated without any
further stimulus in the control media. This could be due to
the presence of unknown chemoattracting agents which at-
tract canine BMSCs more efficiently that the other species
tested. Nervertheless, canine HCM still boosted migration
of canine BMSCs significantly.towards recombinant VEFG-A or HCM. HUVECs served as positive
ia or HCM were calculated using T test. p values <0.05 were
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(from 40- 1990 pg/ml) and high concentrations of HMGB1
(8077-25151 pg/ml). The key for effective migration of
BMSCs seems to be the combination of both and other
factors present in HCM.
Generation of HCM is easy and cheap compared to
preparation and purification of recombinant proteins.
Hence, HCM can be applied in large animals (e.g. sheep,
horse or dogs) for attraction of BMSCs into tissue defects
caused by tumour resection or trauma.
Conclusions
In this study we show that HCM has a species-specific
chemoattractive capacity for human, ovine, equine and
canine BMSCs. Generation of HCM is inexpensive and
provides biologically active chemoattractive agents with-
out time-consuming and expensive processes of protein
enrichment or purification of recombinant proteins. The
aim of future studies will be to apply HCM in vivo in large
animals to stimulate tissue regeneration by attraction of
BMSCs to areas of tissue defects.
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